Clarus Therapeutics (CRXT) Tops Q4 EPS by 49c

Clarus Therapeutics (NASDAQ: CRXT) reported Q4 EPS of ($0.19), $0.49 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $4.64 million.

For earnings history and earnings-related data on Clarus Therapeutics (CRXT) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
• Benchmark Reiterates Buy Rating on Jumia Technologies (JMIA)